Company news

AstraZeneca PLC news in 2022

AstraZeneca PLC's news releases, calls and decks from 2022, newest first.

View company

Calquence Japan approval for treatment-naïve CLL

December 28, 2022

Imfinzi, Imjudo approved in Japan for 3 cancers

December 28, 2022

Lynparza approved in EU for prostate cancer

December 21, 2022

Imfinzi approved in EU for biliary tract cancer

December 21, 2022

Enhertu recommended for EU approval in HER2-low BC

December 19, 2022

Enhertu approved in EU for gastric cancer

December 19, 2022

Imfinzi + Imjudo recommended for approvals in EU

December 19, 2022

Update on Imfinzi PEARL trial

December 19, 2022

Forxiga CHMP opinion for symptomatic chronic HF

December 19, 2022

Update on US review of Lynparza PROpel sNDA

December 15, 2022

Capivasertib PFS in HR-positive breast cancer

December 8, 2022

AstraZeneca announces sale of West Chester site

November 30, 2022

AstraZeneca to acquire Neogene Therapeutics

November 29, 2022

Enhertu recommended for EU approval in gastric

November 14, 2022

Imfinzi recommended for approval in the EU for BTC

November 14, 2022

Lynparza combo recommended in the EU for mCRPC

November 14, 2022

Imfinzi + Imjudo approved in US for lung cancer

November 11, 2022

YTD and Q3 2022 Results

November 10, 2022

FDA Advisory Committee recommends PT027 in asthma

November 9, 2022

Beyfortus (nirsevimab) approved in EU

November 4, 2022

Capivasertib Phase III trial met primary endpoints

October 26, 2022

Update on MESSINA Phase III trial

October 25, 2022

Imfinzi + Imjudo approved in advanced liver cancer

October 24, 2022

Koselugo approved in Japan for NF1

September 27, 2022

Tezspire approved in Japan for severe asthma

September 27, 2022

Ultomiris approved in EU for gMG

September 23, 2022

Lynparza approved in China for ovarian cancer

September 22, 2022

Tezspire approved in the EU for severe asthma

September 21, 2022

Evusheld approved in EU for COVID-19 treatment

September 20, 2022

Danicopan Phase III trial met primary endpoint

September 16, 2022

Evusheld positive CHMP opinion in EU

September 16, 2022

Nirsevimab recommended for approval in EU by CHMP

September 16, 2022

Forxiga approved in China for CKD

September 5, 2022

Imfinzi approved in US for biliary tract cancer

September 5, 2022

Evusheld approved for COVID-19 in Japan

August 30, 2022

Farxiga shows CV mortality benefit across EF range

August 30, 2022

Farxiga reduced risk of CV death or worsening HF

August 30, 2022

Ultomiris approved in Japan for gMG

August 25, 2022

Tagrisso approved in Japan for early lung cancer

August 25, 2022

Lynparza approved in Japan for early breast cancer

August 25, 2022

Lynparza granted FDA priority review for PROpel

August 16, 2022

Enhertu improved PFS in mBC in DESTINY-Breast02

August 15, 2022

Enhertu approved in US for HER2-mutant NSCLC

August 12, 2022

Acquisition of TeneoTwo completed

August 11, 2022

Enhertu approved in the US for HER2-low mBC

August 8, 2022

Lynparza approved in EU for early breast cancer

August 4, 2022

Chair succession

July 29, 2022

Tezspire recommended for EU approval in asthma

July 25, 2022

Ultomiris recommended for EU approval for gMG

July 25, 2022

Enhertu granted Priority Review for HER2-low mBC

July 25, 2022

Older news releases →

Calls in 2022

Decks in 2022